Latest Monoclonal antibodies Stories
HATFIELD, Pa., March 26, 2015 /PRNewswire/ -- Genisphere LLC, provider of the 3DNA(®) nanotechnology platform, reported today it has achieved specific immunodepletion of problematic Myo/Nog
DALLAS, March 24, 2015 /PRNewswire/ -- According to a new market research report " Protein Engineering Market by Technology (Rational Protein Design, Irrational Protein
- New data at AAD shows 7 out of 10 psoriasis patients who were PASI 75 responders at 52 weeks achieved clear to almost clear skin (PASI 90) after two years of Cosentyx 300 mg treatment
- Phase IIIb CLEAR study at AAD showed over 21% more psoriasis patients achieved clear to almost clear skin (PASI 90) with Cosentyx(TM) (secukinumab) compared to Stelara® (ustekinumab) at Week 16
DALLAS, March 19, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "PharmaPoint: Rheumatoid Arthritis - US and 5EU Drug Forecast and Market Analysis to 2023" report provides
MONROVIA, Calif., March 19, 2015 /PRNewswire/ -- Xencor, Inc.
DALLAS, March 18, 2015 /PRNewswire/ -- RnRMarketResearch.com adds "Methotrexate (Rheumatoid Arthritis) - Forecast and Market Analysis to 2023" market research report provides
Pivotal Results Comparing Brodalumab With Stelara® (Ustekinumab) and Placebo to be Presented in Late-Breaking Session THOUSAND OAKS, Calif., March 17, 2015 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
- 22 abstracts further evaluate the safety, efficacy of HUMIRA in psoriatic arthritis and moderate to severe chronic plaque psoriasis and investigational use of HUMIRA for the treatment of moderate
NantCell To Acquire Exclusive Rights to Antibodies Including CAR-TNK(TM) Products and the Checkpoint Inhibitors PD-1 and PD-L1 SAN DIEGO, Mar.
- a slit in a tire to drain away surface water and improve traction.
More Images (1 images) »